心血管疾病是当今世界威胁人类健康的头号杀手，心力衰竭是众多心血管疾病的终点。随着人口老龄化的发展和新的心力衰竭亚型的出现，传统抗心力衰竭药物的疗效难以令人满意。近年来，新型降糖药钠–葡萄糖协同转运蛋白2（SGLT2）抑制剂在心血管结局研究中表现出了良好的效果，展现了此类药物巨大的研究价值。从临床试验结果、心脏功能改善和作用机制分析3个方面综述SGLT2抑制剂治疗心力衰竭的研究进展。

Cardiovascular disease is the number one killer threatening human health in the world today, and heart failure is the end point of many cardiovascular diseases. With the development of the aging population and the emergence of new heart failure subtypes, the efficacy of traditional anti-heart failure drugs is not satisfactory. In recent years, new-type hypoglycemic drugs sodium glucose transporter 2 (SGLT2) inhibitors have shown good effects in cardiovascular outcome studies, demonstrating the tremendous research value of such drugs. This article reviews the research progress of SGLT2 inhibitors on heart failure from three aspects:clinical trial results, cardiac function improvement and potential mechanism analysis.

R972

国家科技重大专项重大新药创制项目（2019ZX09201005-007）